These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 19097649

  • 21. Charge optimization of the interface between protein kinases and their ligands.
    Sims PA, Wong CF, McCammon JA.
    J Comput Chem; 2004 Aug; 25(11):1416-29. PubMed ID: 15185335
    [Abstract] [Full Text] [Related]

  • 22. Kinomics: characterizing the therapeutically validated kinase space.
    Vieth M, Sutherland JJ, Robertson DH, Campbell RM.
    Drug Discov Today; 2005 Jun 15; 10(12):839-46. PubMed ID: 15970266
    [Abstract] [Full Text] [Related]

  • 23. Entry into a new class of protein kinase inhibitors by pseudo ring design.
    Furet P, Caravatti G, Guagnano V, Lang M, Meyer T, Schoepfer J.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):897-900. PubMed ID: 18248988
    [Abstract] [Full Text] [Related]

  • 24. Structure-based design of molecular cancer therapeutics.
    van Montfort RL, Workman P.
    Trends Biotechnol; 2009 May 01; 27(5):315-28. PubMed ID: 19339067
    [Abstract] [Full Text] [Related]

  • 25. Predicting polypharmacology by binding site similarity: from kinases to the protein universe.
    Milletti F, Vulpetti A.
    J Chem Inf Model; 2010 Aug 23; 50(8):1418-31. PubMed ID: 20666497
    [Abstract] [Full Text] [Related]

  • 26. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
    Aronov AM, McClain B, Moody CS, Murcko MA.
    J Med Chem; 2008 Mar 13; 51(5):1214-22. PubMed ID: 18288794
    [Abstract] [Full Text] [Related]

  • 27. Selectivity assessment of kinase inhibitors: strategies and challenges.
    Luo Y.
    Curr Opin Mol Ther; 2005 Jun 13; 7(3):251-5. PubMed ID: 15977423
    [Abstract] [Full Text] [Related]

  • 28. Productive induced metastability in allosteric modulation of kinase function.
    Montes de Oca J, Rodriguez Fris A, Appignanesi G, Fernández A.
    FEBS J; 2014 Jul 13; 281(13):3079-91. PubMed ID: 24823615
    [Abstract] [Full Text] [Related]

  • 29. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery.
    Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP.
    J Med Chem; 2008 Sep 11; 51(17):5149-71. PubMed ID: 18710211
    [No Abstract] [Full Text] [Related]

  • 30. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.
    Chène P.
    Drug Discov Today; 2008 Jun 11; 13(11-12):522-9. PubMed ID: 18549979
    [Abstract] [Full Text] [Related]

  • 31. A chemical genetic method for generating bivalent inhibitors of protein kinases.
    Hill ZB, Perera BG, Maly DJ.
    J Am Chem Soc; 2009 May 20; 131(19):6686-8. PubMed ID: 19391594
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ, Xiang ML, Jia R, Yang SY.
    Yao Xue Xue Bao; 2007 Dec 20; 42(12):1232-6. PubMed ID: 18338633
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Halogen bonding--a novel interaction for rational drug design?
    Lu Y, Shi T, Wang Y, Yang H, Yan X, Luo X, Jiang H, Zhu W.
    J Med Chem; 2009 May 14; 52(9):2854-62. PubMed ID: 19358610
    [Abstract] [Full Text] [Related]

  • 36. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Markland W, Namchuk MN, Nanthakumar S, Poondru S, Straub J, ter Haar E, Xie X.
    J Med Chem; 2009 Oct 22; 52(20):6362-8. PubMed ID: 19827834
    [Abstract] [Full Text] [Related]

  • 37. Turning promiscuous kinase inhibitors into safer drugs.
    Zhang X, Crespo A, Fernández A.
    Trends Biotechnol; 2008 Jun 22; 26(6):295-301. PubMed ID: 18403035
    [Abstract] [Full Text] [Related]

  • 38. Elucidation of characteristic structural features of ligand binding sites of protein kinases: a neural network approach.
    Niwa T.
    J Chem Inf Model; 2006 Jun 22; 46(5):2158-66. PubMed ID: 16995746
    [Abstract] [Full Text] [Related]

  • 39. The identification of new protein kinase inhibitors as targets in modern drug discovery.
    Akritopoulou-Zanze I.
    IDrugs; 2006 Jul 22; 9(7):481-7. PubMed ID: 16821161
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.